Online vs Community pharmacies
It is going to be interesting to watch the continued tussle between the online and community pharamacy sectors. Both offer convincing...
Life Sciences
Contributors
-
Solicitor -
-
Of Counsel -
Partner -
Senior Associate -
-
-
-
Partner -
Senior Associate (Rechtsanwalt) -
Corporate Associate -
Senior Associate -
-
-
Special Counsel -
Marketing & Business Development Manager
-
Partner -
-
-
-
-
Marketing Coordinator, International Practice Groups & Sectors
-
Partner -
Partner -
Global Co-Chair Life Science Partner -
Senior Marketing Manager -
-
-
-
Lawyer -
-
-
Senior Associate -
Partner, Healthcare Industry Sector -
Partner -
-
Partner -
Associate
-
-
-
-
-
Associate
-
Senior Associate -
Partner, Head of Patents
DLA Piper Life Sciences Archive
- November 2020 (6)
- October 2020 (5)
- September 2020 (4)
- July 2020 (2)
- June 2020 (1)
- May 2020 (2)
- April 2020 (6)
- March 2020 (1)
- February 2020 (2)
- January 2020 (4)
- November 2019 (2)
- October 2019 (1)
- August 2019 (1)
- July 2019 (5)
- May 2019 (6)
- March 2019 (2)
- February 2019 (4)
- January 2019 (1)
- December 2018 (2)
- November 2018 (2)
- October 2018 (1)
- August 2018 (1)
- July 2018 (2)
- May 2018 (1)
- April 2018 (3)
- March 2018 (8)
- February 2018 (1)
- December 2017 (5)
- November 2017 (15)
- October 2017 (7)
Consolidation is the name of the game for our public healthcare system
Very interesting article about the vision of the NHS to transform and consolidate our public healthcare system to drive further...
Webinar discussing the fallout from the up coming EU summit and what it may mean to businesses in areas such as the Life Sciences.
Join members of DLA Piper's Brexit Committee for a webinar hosted right after this weeks EU summit ends. They will cut through the noise...
Some Brexit clarity.....to end of 2020
A Brexit transition period to 31 December 2020 is good news for the Life Sciences industry. Brexit negotiators have now agreed...
Publishing Clinical Data under Policy 0070
We have been looking closely at the EMA requirements for publishing clinical data under Policy 0070. There is an expanding body of...
What’s in a name? The Latest Considerations in Naming Biosimilars
Really looking forward to meeting you at the IP Forum for Life Sciences in April. I will be hosting a discussion with tregard to naming...
Northern Powerhouse going global
Tomorrow I will be on stage at 11 am discussing 'Growing Global' at the Northern Powerhouse Health Innovation Conference 2018.
The...
Pharma and biotech legal developments - C5 conference report
I spent two fascinating days at the C5 Pharma and biotech conference last week. Some of the more interesting takeaways:
- in determining the...
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at sales@passle.net